REBYOTA® Guide for Leveraging CERNER Electronic Health Record

FUNCTIONALITY TO SUPPORT IMPLEMENTATION

REBYOTA® (fecal microbiota, live-jslm) suspension, for rectal use


GO BEYOND

Please see Important Safety Information on the last page and full Prescribing Information.

Background

This guide is intended to assist healthcare providers (HCPs) and health systems in configuring their EMR/EHR to facilitate prescribing of REBYOTA® (fecal microbiota, live – jslm) indicated for the prevention of recurrence of Clostridioides difficile infection (CDI). Functions, locations, and terminology used in this guide may differ based on the software version implemented within a facility. This guide should not replace instructions from your internal or external EHR support teams. Ferring does not endorse any specific EHR systems.

This document is for informational purposes only. All clinical decisions are the responsibility of the HCP, and the examples provided in this guide are not meant as guidance for medical treatment. This document is not intended to provide any clinical recommendations, as treatment decision-making is the sole responsibility of an HCP.



Cerner Instructions


Considerations

Electronic health record (EHR) systems and hospital and health system processes will vary. Modify procedures within this document as necessary to meet your institutional needs. It is the responsibility of the medical group to implement, test, monitor, and ensure the ongoing operation of any EHR tools. A new order set will be available once the optimization process is complete. If the original order set used to update or create the new order set includes REBYOTA, confirm the original order set is retired.

NOTE
If REBYOTA is not available for selection in Cerner, the practice may need to run a drug database update. Alternatively, the institution's IT department may manually add REBYTOA in accordance with its business rules for drug database management.

Adding REBYOTA to existing PowerPlan


1. From the DCP Tool, launch the PowerPlan Tool. Select Open Existing Plan
2. From the Plan Selection window, select the appropriate Plan
3. Select OK
4. If the PowerPlan has multiple phases, from the Description column, select the phase




5. Select the Prescription tab in the lower-right section of the main window
6. Enter text into the Start search at box and click the Find button to search or orderable items, such as REBYOTA
7. Select the item or items in the Search results box to add to the PowerPlan. Click the right arrow to add the selected orderable item(s) to the Current list



8. From the Order Sentence tab under the Order Sentences header, move all appropriate instructions to the Current list.
   • Administration: For Preparation and Administration, please refer to the Prescribing Information here: **https://www.ferringusa.com/wp-content/uploads/sites/12/2022/12/9009000002_REBYOTA-PI_11-2022.pdf**



9. Select Add to add items from the Current list to the Order Set. The component is displayed in the Description column
10. Select Save
11. Similarly, add other appropriate Orders (e.g., lab or patient education Orders) according to HCP clinical judgment to complete the Order Set
12. Select the phase appropriate for the Order, such as laboratory or patient education
13. Select the Order tab. Search for and select lab orders
14. Select Add for each additional item and add Order Sentence as needed
15. Select Save Description from the toolbar



REBYOTA®
(fecal microbiota, live-jslm) suspension, for rectal use

INDICATION

REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of *Clostridioides difficile (C. diff)* infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.

Limitation of Use

REBYOTA is not indicated for the treatment of *C. diff* infection.

IMPORTANT SAFETY INFORMATION

- You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
- You should report to your doctor any infection you think you may have acquired after administration.
- REBYOTA may contain food allergens.
- Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
- REBYOTA has not been studied in patients below 18 years of age.
- Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit **www.FDA.gov/medwatch** or call 1-800-332-1088.

Please see full Prescribing Information available at **www.REBYOTAhcp.com**.

©2026 Ferring. REBYOTA, Ferring and the Ferring Pharmaceuticals logo are trademarks of Ferring.
US-REB-2600013 07/26

FERRING PHARMACEUTICALS

Microbiome Therapeutics Development